Novo Holdings Completes Acquisition of Catalent Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership SOMERSET, NJ and

Novo Holdings Completes Acquisition of Catalent

Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership

SOMERSET, NJ and COPENHAGEN, Denmark December 18, 2024 Catalent, Inc. ( Catalent ), a leader in enabling the

development and supply of better treatments for patients worldwide, and Novo Holdings A/S ( Novo Holdings ), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of

Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion.

Maselli, who will remain President and Chief Executive Officer of Catalent, said, The completion of this transaction marks a significant milestone for Catalent. As a private company with Novo Holdings partnership and support, we are

well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders. I would like to thank all of our employees for their commitment to making Catalent the incredible

company it is today, and I am excited for all that we will accomplish going forward.

Kasim Kutay, CEO of Novo Holdings, said, We are pleased

to welcome Alessandro and the talented Catalent team to the Novo Holdings family. Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is

closely aligned with Novo Holdings purpose to invest for the benefit of people and the planet.

We look forward to supporting the

Catalent team as they build on their positive momentum and position the company for future growth to the benefit of customers and patients globally, added Jonathan Levy, Senior Partner, Novo Holdings.

With the completion of the transaction, holders of Catalent common stock are entitled to receive $63.50 per share in cash, representing a premium of

approximately 47.5% to the 60-day volume-weighted average price as of February 2, 2024. Catalent s common stock has ceased trading and will be delisted from the New York Stock Exchange.

Shortly following the completion of the transaction, Novo Nordisk A/S will acquire from Novo Holdings Catalent s three fill-finish sites located in

Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium, and related assets.

Citi and J.P. Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Catalent and Jones

Day served as legal advisor to the Catalent Board of Directors. Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Davis Polk &

Wardwell LLP and Arnold & Porter Kaye Scholer LLP served as legal advisors to Novo Nordisk.

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products

that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested

experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists

and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.

Novo Holdings is a holding and

investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people s health and the sustainability of society and the planet by generating attractive

long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder

of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo

Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

About the Novo Nordisk Foundation

Established in Denmark

in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people s health and the sustainability of society and the planet. The Foundation s mission is to

progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

Global media inquiries: Marie-Louise

Jersin, Senior Communications Partner

US media inquiries: Dora Gonzalez, Public Relations Specialist